|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
08-05-2010, 12:57 PM
|
|||
|
|||
Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in ...
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cance | cancerfr | Ovarian Cancer | 0 | 08-05-2010 12:57 PM |
| Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted co | cancerfr | Endometrial Cancer | 0 | 06-29-2010 11:22 AM |
| Aeterna Zentaris Announces Phase 1 Data of Single Agent Perifosine in the Treatment o | cancerfr | Neuroblastoma | 0 | 06-09-2010 10:27 PM |
| Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer | cancerfr | Endometrial Cancer | 0 | 06-07-2010 07:43 PM |
Linear Mode
